I-CAR T (Iseli ye-Chimeric Antigen Receptor-T) 

Izinhlelo zokwelashwa kwamaselula zika-Sorrento zigxile ku-Chimeric Antigen Receptor-T Cell (CAR T) yokwamukela i-immunotherapy yamaselula ukwelapha womabili amathumba aqinile nawuketshezi. 

Uhlelo lwe-CAR T luhlanganisa i-CD38, CEA ne-CD123.

I-CD38 CAR T ye-Sorrento iqondise kumaseli e-CD38 aveza amazwi aphezulu, angase akhawulele ubuthi obukhona lapho kuqondiswe khona/ukususa isimila.

Ikhandidethi lenkampani le-CD38 CAR T okwamanje liyahlolwa ku-multiple myeloma (MM). Uhlelo lubonise ngempumelelo umsebenzi oqinile we-preclinical anti-tumor kumamodeli ezilwane futhi okwamanje lukuhlolo lwesigaba 1 ku-RRMM. Ukwengeza, i-Sorrento ibike idatha evela kuhlolo lweSigaba I se-carcinoembryonic antigen (CEA) eqondiswe kuhlelo lwe-CAR T.

Inkampani ihlola i-CD123 CAR T ku-acute myeloid leukemia (AML).

I-DAR T (Iseli ye-Dimeric Antigen Receptor-T)

I-Sorrento isebenzisa ubuchwepheshe be-knock-out (KOKI) obuphathelene nokuphathelene ukuze iguqule amaseli e-T atholakala kumnikeli onempilo ukuze awenze ngofuzo ukuze aveze isamukeli se-antigen ye-dimeric ku-T-cell receptor (TCR) i-alpha chain constant region (TRAC). Ngale ndlela, i-TRAC ikhishwa bese i-antigen ishaywa endaweni yayo. 

I-Dimeric Antigen Receptor (DAR) isebenzisa i-Fab esikhundleni se-scFv esetshenziswa amaseli T we-Chimeric Antigen Receptor (CAR) T. Sikholelwa ukuthi le DAR iboniswe ocwaningweni lwangaphambi komtholampilo ukucaciswa okukhulu, ukuqina namandla.

Ama-Chimeric Antigen Receptors (ama-CAR)